Advertisement

Moderna Starts a Phase 2 Clinical Trial for Its COVID-19 Vaccine

Moderna Starts a Phase 2 Clinical Trial for Its COVID-19 Vaccine

Moderna (NASDAQ: MRNA) has enrolled the first participants in a phase 2 clinical trial testing mRNA-1273, its vaccine against the novel coronavirus that causes COVID-19. Moderna announced plans to start the mid-stage study in April, followed by an endorsement by the Food and Drug Administration last month. Moderna plans to enroll 600 participants in the study, with half of them being 55 years of age or older.